• 한국진공학회:학술대회논문집
• /
• 한국진공학회 2013년도 제44회 동계 정기학술대회 초록집
• /
• pp.83-83
• /
• 2013

To date, various nanobiotechnologicalapproaches for biosensors and drug development have been explosively studied. Despite of successful demonstrations, the new technologies hardly enjoyed routine applications in practical nanobiomedicine. Here, researchers trained at the interface of basic sciences and engineering are expected to play critical roles. In this tutorial, I will introduce recent studies which harness graphene derivatives for developing bioanalytical platforms to quantitatively analyze various enzyme activities and biomarkers. The systems rely on attractive interaction between graphene oxide and nucleic acids or phospholipids. Recently, one of the graphene-based bioassay system was applied to anti-viral drug screening and potent hit compounds were identified to treat hepatitis C. This study clearly shows that a new nanobio-technology can be routinely implemented in drug discovery, providing many advantages over conventional methods.

• Genomics & Informatics
• /
• 제14권1호
• /
• pp.2-11
• /
• 2016

The advances in mass spectrometry-based proteomics technologies have enabled the generation of global proteome data from tissue or body fluid samples collected from a broad spectrum of human diseases. Comparative proteomic analysis of global proteome data identifies and prioritizes the proteins showing altered abundances, called differentially expressed proteins (DEPs), in disease samples, compared to control samples. Protein biomarker candidates that can serve as indicators of disease states are then selected as key molecules among these proteins. Recently, it has been addressed that cellular pathways can provide better indications of disease states than individual molecules and also network analysis of the DEPs enables effective identification of cellular pathways altered in disease conditions and key molecules representing the altered cellular pathways. Accordingly, a number of network-based approaches to identify disease-related pathways and representative molecules of such pathways have been developed. In this review, we summarize analytical platforms for network-based protein biomarker discovery and key components in the platforms.

• 한국정보통신학회:학술대회논문집
• /
• 한국해양정보통신학회 2005년도 추계종합학술대회
• /
• pp.82-85
• /
• 2005

이동 Pv6(MIPv6)를 지원하는 네트워크에서 이동 노드(mobile node)가 새로운 네트워크로 이동했을 때 그 네트워크에서의 엑세스 라우터와 엑세스 포인트(Access Router/Access Point)를 찾아 연결해야 한다. 이때 신뢰할 수 있는 AR과 AP에 연결하지 못할 경우 여러 형태의 공격에 노출된다. 본 논문에서는 SEcure Neighbor Discovery(SEND)에서 사용하는 공개키 기반 RSA 암호화 방식을 응용하여 AR/AP와 MN이 상호 인증할 수 있는 방안을 제시한다.

• Architectural research
• /
• 제12권2호
• /
• pp.1-7
• /
• 2010

Science (natural science) is the systematic attempt to understand and interpret the nature phenomenon. For this reason, architects have used science to adapt nature to their design. With the rise of modern science, architecture became more closely related with science. Science available to develop new technology for architecture and it influenced architect's idea and concept. Symbolically, Architects use method or process of science to generate building form. The Rules of compositing particles in the chemistry or DNA (deoxyribonucleic acid) in the biology are used to generate a form of building. Literally, Architects use technology as a tool of science to improve physical performance of architecture. Like mathematical understanding of structure load enabled people to construct enclosure without columns or any of support system inside of architecture. Still natural phenomenon is not fully understood as science and science is still discovering a new phenomenon or changing its theory to adapt new discovery. New discovery or limitation of science influenced architecture throughout the history. This paper is to discuss how architectural theories are rest upon idea set forth by science. In addition, how technology as a tool of science has been utilized in architecture.

• Journal of Genetic Medicine
• /
• 제20권2호
• /
• pp.31-38
• /
• 2023

Rare diseases, even though defined as fewer than 20,000 in South Korea, with over 8,000 rare Mendelian disorders having been identified, they collectively impact 6-8% of the global population. Many of the rare diseases pose significant challenges to patients, patients' families, and the healthcare system. The diagnostic journey for rare disease patients is often lengthy and arduous, hampered by the genetic diversity and phenotypic complexity of these conditions. With the advent of next-generation sequencing technology and clinical implementation of exome sequencing (ES) and genome sequencing (GS), the diagnostic rate for rare diseases is 25-50% depending on the disease category. It is also allowing more rapid new gene-disease association discovery and equipping us to practice precision medicine by offering tailored medical management plans, early intervention, family planning options. However, a substantial number of patients remain undiagnosed, and it could be due to several factors. Some may not have genetic disorders. Some may have disease-causing variants that are not detectable or interpretable by ES and GS. It's also possible that some patient might have a disease-causing variant in a gene that hasn't yet been linked to a disease. For patients who remain undiagnosed, reanalysis of existing data has shown promises in providing new molecular diagnoses achieved by new gene-disease associations, new variant discovery, and variant reclassification, leading to a 5-10% increase in the diagnostic rate. More advanced approach such as long-read sequencing, transcriptome sequencing and integration of multi-omics data may provide potential values in uncovering elusive genetic causes.

• 대한화학회지
• /
• 제53권6호
• /
• pp.653-662
• /
• 2009

흡수, 분포, 대사, 배설 특성 및 독성을 예측하기 위한 효과적인 툴을 개발하는 것은 신약개발의 초기단계에서 NCE(new chemical entity)에 대한 가장 중요한 업무 중의 하나이다. 최근에 이런 시도중의 하나로서 ADME/T(absorption, distribution, metabolism, excretion, toxicity)관련 성질들의 예측에 support vector machine(SVM)을 이용하고 있다. 그리고 SVM은 ADME/T 성질들을 정확하게 예측하는데 많이 사용 되고 있다. 그러나 SVM 모델링에 두 가지 문제가 있다. 특성 선택(feature selection) 과 매개변수 설정(parameter setting)은 여전히 해결해야 할 과제이다. 이 두 가지 문제들은 SVM 분류의 효율성과 정확도에 결정적인 영향을 끼친다. 특히 특성 선택과 최적화된 SVM 변수의 설정은 서로 영향을 주기 때문에 동시에 다루어져야 한다. 여기서 우리는 genetic algorithm(GA) – 특성 선택에 사용 – 과 grid search(GS) method– 변수최적화에 사용 – 두 가지를 통합하는 효과적인 해결책을 제시하였다. ADME/T관련 성질 중 하나인 심장부정맥을 야기시키는 hERG 이온채널 저해제 분류 모델이 여기서 제안된 GA-GS-SVM을 위해 할당되고 테스트 되었다. 1891개의 화합물을 가지는 트레이닝 셋으로 단일 모델 3개, 앙상블 모델 3개, 총 6개의 모델을 만들었고 175개의 외부 데이터를 테스트 셋으로 사용하여 검증하였다. 데이터의 불균형 문제를 해결하기 위하여 GA-GS-SVM 단일 모델에 의한 예측 정확도와 GA-GS-SVM 앙상블 모델 예측 정확도를 비교하였으며, 앙상블모델을 사용하여 예측의 정확도를 높일 수 있었다.

• 대한약학회:학술대회논문집
• /
• 대한약학회 2000년도 춘계총회 및 학술대회
• /
• pp.64-65
• /
• 2000

• 한국미생물학회:학술대회논문집
• /
• 한국미생물학회 2009년도 International Meeting of the Microbiological Society of Korea
• /
• pp.68-69
• /
• 2009

• 천문학회보
• /
• 제25권1호
• /
• pp.43-43
• /
• 2000

• 한국생물물리학회:학술대회논문집
• /
• 한국생물물리학회 2003년도 정기총회 및 학술발표회
• /
• pp.55-55
• /
• 2003

P2X$_3$ receptor, a member of P2 purine receptors, is a ligand-gated ion channel activated by extracellular ATP as an endogenous ligand, and highly localized in peripheral and central sensory neurons. The activation of P2X3 receptor by ATP as the pronociceptive effect has been known to initiate the pain signaling involved in chronic inflammatory nociception and neuropathic pain by nerve injury, implicating the possibility of new drug development to control pains. In this study, we have developed a two electrode voltage clamp (TEVC) assay system to evaluate the inhibitory activity of several newly synthesized PPADS and a novel non-ionic antagonist against ATP activation of human P2X3 receptor. PPADS derivatives include several pyridoxine and pyridoxic acid analogs to study the effects of phosphate and aldehyde functional groups in PPADS. All new PPADS analogs were less potent than PPADS at human P2X$_3$ receptors, however, LDD130, a non-ionic analog showed potent antagonistic property with $IC_{50}$/ of 8.34 pM. In order to uncover the structure activity relationships of LDD130, and design new structural analogs, we synthesized and investigated a few structural variants of LDD130, and the results will be discussed in this presentation.